- In April 2025, UC Davis Health launched a new cell therapy trial targeting chronic kidney disease in patients with type 2 diabetes. This novel approach, aimed at restoring kidney function, highlights growing innovation in regenerative medicine and is expected to create new growth opportunities within the kidney disease market by advancing alternative, potentially curative treatment options
- In September 2023, the FDA approved empagliflozin (Jardiance) for treating kidney disease in adults. As a once-daily 10 mg pill, it significantly reduced the risk of eGFR decline, kidney failure, hospitalization, and cardiovascular death in trials. This approval is expected to strengthen the kidney disease market by expanding effective treatment options and driving growth in the SGLT2 inhibitor segment
